← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Aflac remains a Japan-heavy supplemental insurer, with FY2025 revenue and earnings down while capital returns rose.
The read at a glance✓ Audited against SEC data
- Growth — Revenue -9.3% to $17.16BWatch
- Profitability — Net income -33.0% to $3.65BWatch
- Cash — Operating cash flow -5.6%Watch
- Margins — Net margin -752 bps to 21.24%Watch
- Capital — Buybacks +26.1%; dividends +10.2%Note
- Insiders — 0 open-market buys / 76 sellsWatch
Business
Aflac sells supplemental health and life insurance in Japan and the United States. The core promise is simple: cash benefits when policyholders face covered sickness, injury, hospitalization, cancer, disability, or related events.
Where the revenue comes from
Fiscal 2025, as AFLAC INC reports it. History and quarterly detail are in the app.
- Aflac Japan$9.4B
- Aflac U.S.$6.9B
- Corporate and other$1.3B
Leadership changes
From AFLAC INC's own filings, the day they're filed.
- Aflac Incorporated · Chairman · appointmenteff. 2024-01-01
- Robin Blackmon · President · appointmenteff. 2023-12-31
- Aflac Incorporated · Directors · departureeff. 2023-06-09
Latest filings
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-06-30
- 8-K · Company announcement2026-05-28
- 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about AFLAC INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.